Institution
Argerich Hospital
Healthcare•Buenos Aires, Argentina•
About: Argerich Hospital is a healthcare organization based out in Buenos Aires, Argentina. It is known for research contribution in the topics: Population & Osteoporosis. The organization has 213 authors who have published 154 publications receiving 3716 citations. The organization is also known as: Hospital General de Agudos Dr. Cosme Argerich.
Topics: Population, Osteoporosis, Embolism, Bundle branch block, Plastic surgery
Papers published on a yearly basis
Papers
More filters
••
McMaster University1, Eli Lilly and Company2, Columbia University3, Katholieke Universiteit Leuven4, Karolinska Institutet5, University of Oxford6, University of Sheffield7, Aarhus University Hospital8, Argerich Hospital9, Università Campus Bio-Medico10, Medical University of Graz11, University of Edinburgh12, Royal North Shore Hospital13, Sinai University14, University of Las Palmas de Gran Canaria15, Charles University in Prague16, Cambridge University Hospitals NHS Foundation Trust17, International Osteoporosis Foundation18
TL;DR: Guidance for glucocorticoid-induced osteoporosis is updated in the light of new treatments and methods of assessment, and national guidelines derived from this resource need to be tailored within the national healthcare framework of each country.
Abstract: Summary
This paper provides a framework for the development of national guidelines for the management of glucocorticoid-induced osteoporosis in men and women aged 18 years and over in whom oral glucocorticoid therapy is considered for 3 months or longer.
286 citations
••
TL;DR: Amiodarone hydrochloride proved to be highly effective in preventing and treating arrhythias of the Wolff-Parkinson-White (WPW) syndrome in 11 patients with WPW conduction and recurrent tachyarrhythmias.
Abstract: Amiodarone hydrochloride proved to be highly effective in preventing and treating arrhythmias of the Wolff-Parkinson-White (WPW) syndrome in 11 patients with WPW conduction and recurrent tachyarrhythmias Paroxysmal supraventricular tachycardia (six patients), atrial fibrillation (four patients) and atrial flutter (one patient) were the most significant arrhythmias In most patients the arrhythmia was seriously disabling because of the extremely rapid ventricular rate, adverse hemodynamic consequences and frequent recurrence and long duration of the episodes Other known antiarrhythmic agents were ineffective In all 11 patients amiodarone, in doses of 300 to 600 mg daily, totally, easily and safety controlled the arrhythmias for periods of 2 to 8 months The drug was fully effective after an average of 7 days of treatment Tolerance to amiodarone was excellent The occurrence of corneal microdeposits of the drug was the only Important undesirable effect, but subjective ocular disturbances were not noted The microdeposits are reversible, and can be avoided by discontinuing the drug for 7 days every 1 to 2 months Amiodarone apparently causes a significant prolongation of refractoriness in the normal (A-V node and His-Purkinje system) as well as in the anomalous pathway, thus creating favorable conditions for prevention and Interruption of any reentry mechanism requiring participation of both pathways
249 citations
••
TL;DR: The efficacy of 20% azelaic acid cream and 4% hydroquinone cream, both used in conjunction with a broad‐spectrum sunscreen, against melasma was investigated in a 24‐week, doubleblind study with 329 women.
Abstract: The efficacy of 20% azelaic acid cream and 4% hydroquinone cream, both used in conjunction with a broad-spectrum sunscreen, against melasma was investigated in a 24-week, double-blind study with 329 women. Over the treatment period the azelaic acid cream yielded 65% good or excellent results; no significant treatment differences were observed with regard to overall rating, reduction in lesion size, and pigmentary intensity. Severe side effects such as allergic sensitization or exogenous ochronosis were not observed with azelaic acid.
187 citations
••
TL;DR: It is concluded that radiographically ascertained vertebra fractures are common in Latin America and health authorities in the region should be aware and consider implementing measures to prevent vertebral fractures.
Abstract: In the first population-based study of vertebral fractures in Latin America, we found a 11.18 (95% CI 9.23–13.4) prevalence of radiographically ascertained vertebral fractures in a random sample of 1,922 women from cities within five different countries. These figures are similar to findings from studies in Beijing, China, some regions of Europe, and slightly lower than those found in the USA using the same standardized methodology. We report the first study of radiographic vertebral fractures in Latin America. An age-stratified random sample of 1,922 women aged 50 years and older from Argentina, Brazil, Colombia, Mexico, and Puerto Rico were included. In all cases a standardized questionnaire and lateral X-rays of the lumbar and thoracic spine were obtained after informed consent. A standardized prevalence of 11.18 (95% CI 9.23–13.4) was found. The prevalence was similar in all five countries, increasing from 6.9% (95% CI 4.6–9.1) in women aged 50–59 years to 27.8% (95% CI 23.1–32.4) in those 80 years and older (p for trend < 0.001). Among different risk factors, self-reported height loss OR = 1.63 (95% CI: 1.18–2.25), and previous history of fracture OR = 1.52 (95% CI: 1.14–2.03) were significantly (p < 0.003 and p < 0.04 respectably) associated with the presence of radiographic vertebral fractures in the multivariate analysis. In the bivariate analyses HRT was associated with a 35% lower risk OR = 0.65 (95% CI: 0.46–0.93) and physical activity with a 27% lower risk of having a vertebral fracture OR = 0.73 (95% CI: 0.55–0.98), but were not statistically significant in multivariate analyses We conclude that radiographically ascertained vertebral fractures are common in Latin America. Health authorities in the region should be aware and consider implementing measures to prevent vertebral fractures.
163 citations
••
TL;DR: Denosumab was both non-inferior and superior to risedronate at 12 months for effect on bone mineral density at the lumbar spine in both glucocorticoid-continuing and glucocortex-initiating subpopulations.
138 citations
Authors
Showing all 218 results
Name | H-index | Papers | Citations |
---|---|---|---|
Marcelo V. Elizari | 29 | 93 | 3421 |
Pablo A. Chiale | 22 | 72 | 2259 |
Julio O. Lázzari | 22 | 36 | 2248 |
Gerardo J. Nau | 18 | 29 | 1683 |
Jorge Orlando Guerrissi | 16 | 47 | 701 |
Osvaldo D. Messina | 16 | 41 | 1058 |
M. Susana Halpern | 14 | 17 | 1312 |
Raúl J. Levi | 14 | 19 | 1426 |
Jorge A. Lax | 12 | 57 | 485 |
María C. Saccheri | 12 | 50 | 477 |
Tomás F. Cianciulli | 12 | 67 | 481 |
Edgardo Schapachnik | 12 | 29 | 507 |
Mauricio B. Rosenbaum | 11 | 12 | 1587 |
Horacio A. Prezioso | 11 | 34 | 402 |
Juan Gagliardi | 9 | 74 | 282 |